TICKERNERD
Menu
STESTEHealthcare · Medical Devices

STE Stock Forecast: STERIS Plc (Ireland) Price Predictions for 2026-2027

Last close, 21 Aug 2026
$238
+0.90% on the day

The 9 Wall Street analysts covering STERIS Plc (Ireland) hold a median 12-month price target of $270 — +13.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 85 of 100 as at 22 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$23.2B
Ticker Nerd rank
85 / 100
Median analyst target
$270
Analysts covering
9
Total return, dividends reinvested
1W
+2.0%
1M
+12.3%
YTD
−5.7%
1Y
−3.1%
From 52W high
−11.0%
From 52W low
+19.3%
$199
$267
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

STE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores STERIS Plc (Ireland) on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
85 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
100
Value
95
Quality
87
Issuance
82
Growth
65
Revisions
62
Accruals
57
Momentum
51
Size
10

Volatility (100): The share price has been relatively steady.

Momentum (51): The shares have been drifting down relative to others.

Size (10): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

STE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on STE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$200$220$240$260$280Oct 25Jan 26Apr 26Jul 26STEHigh $280Median $270Low $232

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says9 analysts
6 Buy3 Hold0 Sell
Low $232Median $270High $280

The green dot is the last close — the median target sits +13.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
7 Aug 2026Piper SandlerReiteratesOverweight$270 → $275
7 Aug 2026UBSMaintainsBuy$275 → $270
28 July 2026UBSInitiatesBuy—
28 July 2026UBSInitiatesBuy$275
13 May 2026KeybancMaintainsOverweight—
13 May 2026KeybancMaintainsOverweight$291 → $269
8 Aug 2025Morgan StanleyMaintainsOverweight—
22 July 2025KeybancMaintainsOverweight—
15 July 2025Morgan StanleyUpgradeOverweight—
29 May 2025JefferiesInitiatesHold—
19 May 2025Morgan StanleyMaintainsEqual-Weight—
16 May 2025JMP SecuritiesMaintainsMarket Outperform—
15 May 2025Stephens & Co.ReiteratesOverweight—
12 May 2025Morgan StanleyMaintainsEqual-Weight—
10 Apr 2025JMP SecuritiesReiteratesMarket Outperform—
7 Apr 2025NeedhamReiteratesHold—
6 Feb 2025JMP SecuritiesReiteratesMarket Outperform—
6 Feb 2025Stephens & Co.ReiteratesOverweight—
3 Feb 2025Piper SandlerMaintainsOverweight—
18 Nov 2024JMP SecuritiesReiteratesMarket Outperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. STE appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

STE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+0.0%
Analysts raising
3
Analysts cutting
1
Fundamentals

STERIS Plc (Ireland) (STE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
29.1×

Cheaper than 28% of US stocks

Price / sales
3.8×

Cheaper than 34% of US stocks

Price / book
3.2×

Cheaper than 33% of US stocks

EV / EBITDA
15.1×

Cheaper than 24% of US stocks

Growth & margins
Revenue growth (YoY)
7.3%

Higher than 45% of US stocks

Earnings growth (YoY)
12.8%

Higher than 51% of US stocks

Gross margin
45.8%

Higher than 57% of US stocks

Operating margin
19.2%

Higher than 78% of US stocks

Net margin
13.3%

Higher than 75% of US stocks

Returns & dividend
Return on equity
11.4%

Higher than 67% of US stocks

Return on assets
6.8%

Higher than 84% of US stocks

Dividend yield
1.1%

Higher than 25% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

STE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
STESTERIS Plc (Ireland)$23.2B
85
ZBHZimmer Biomet Holdings, Inc.$20.0B
91
GEHCGE Healthcare Technologies, Inc.$34.1B
62
DXCMDexCom, Inc.$35.6B
98
PENPenumbra, Inc.$12.8B
76
GMEDGlobus Medical, Inc.$11.7B
96
GKOSGlaukos Corp.$10.9B
91

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own STERIS Plc (Ireland) — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest STE news & analysis

Can STERIS Stock Deliver as Its $600 Million Chemistry Bet Scales?

Zacks Investment Research · 21 Aug 2026neutral

STERIS is investing $600 million in a new chemistry center intended to boost capacity and efficiency, though the move brings higher spending and execution risks. The investment is being scaled up as part of the company's growth strategy.

Why it matters — A STE watcher would care because the $600 million chemistry center represents a significant capital commitment that could affect the company's capacity, efficiency, and financial performance.

Should Investors Buy STERIS as Growth Meets Reasonable Valuation?

Zacks Investment Research · 20 Aug 2026neutral

STERIS enters fiscal 2027 with solid growth, recurring healthcare demand and improved margins, according to a Zacks Investment Research report. However, tariffs and investment needs temper the valuation case as investors weigh the company's outlook.

Why it matters — A STE watcher would care because the report highlights both the company's positive growth drivers and the challenges that could affect its valuation as fiscal 2027 begins.

STERIS Q1 Earnings Call Highlights

MarketBeat · 9 Aug 2026positive

STERIS reported first-quarter fiscal 2027 revenue growth and higher earnings while maintaining its full-year outlook. The company also outlined a $600 million investment in a new chemistry manufacturing, research and distribution complex in North Carolina.

Why it matters — The news reflects ongoing business momentum and a significant expansion commitment for a STE watcher.

STERIS plc (STE) Q1 2027 Earnings Call Transcript

Seeking Alpha · 6 Aug 2026neutral

This item is the published transcript of STERIS plc's fiscal first-quarter 2027 earnings call, sourced from Seeking Alpha. It presents management's discussion of the company's earnings results for the period.

Why it matters — A STERIS watcher would consult this transcript for management's own commentary on the quarterly results and outlook directly from the earnings call.

STE Q1 Earnings Beat, Revenues Miss, Stock Dips in Aftermarket Trading

Zacks Investment Research · 6 Aug 2026neutral

STERIS beat fiscal Q1 earnings estimates as sales rose 7.3% year over year, but a modest revenue miss sent shares 2.4% lower in aftermarket trading.

Why it matters — For a STE watcher, the mixed quarterly result—an earnings beat alongside a revenue miss and aftermarket share decline—shows how the market reacted to the company's latest performance.

FAQ

Frequently asked questions about STE stock

What is the STE stock price forecast for 2026-2027?

The 9 Wall Street analysts covering STERIS Plc (Ireland) have a median 12-month price target of $270, with estimates ranging from $232 to $280. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is STE stock a buy right now?

Of the 9 analysts covering STERIS Plc (Ireland), 6 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks STERIS Plc (Ireland) 85 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank STE?

As at 22 Aug 2026, STERIS Plc (Ireland) ranks 85 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (100 of 100).

Will STE stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +13.3% from the last close, and Ticker Nerd's factor model ranks STERIS Plc (Ireland) 85 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the STE stock forecast for 2030?

No analyst covering STERIS Plc (Ireland) publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for STE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $232 to $280 over the next 12 months.

How has STE stock performed over the past year?

STERIS Plc (Ireland) returned -3.1% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does STERIS Plc (Ireland) do?

STERIS plc is a global healthcare and life sciences company that provides infection prevention and other procedural products and services. The company focuses on helping hospitals, surgery centers, and other medical facilities maintain sterile, safe environments through a broad portfolio of capital equipment, consumables, and technical services.

What is the latest news on STE?

The most recent item we track (Zacks Investment Research, 21 Aug 2026): "Can STERIS Stock Deliver as Its $600 Million Chemistry Bet Scales?". STERIS is investing $600 million in a new chemistry center intended to boost capacity and efficiency, though the move brings higher spending and execution risks. The investment is being scaled up as part of the company's growth strategy.

Company

About STERIS Plc (Ireland).

STERIS plc is a global healthcare and life sciences company that provides infection prevention and other procedural products and services. The company focuses on helping hospitals, surgery centers, and other medical facilities maintain sterile, safe environments through a broad portfolio of capital equipment, consumables, and technical services. Its Healthcare-related offerings include sterilizers, washer-disinfectors, operating room and endoscopy workflow equipment, connectivity solutions, and infection-prevention chemistries and accessories, along with installation, maintenance, and repair services. Through its Applied Sterilization Technologies operations, STERIS supplies contract sterilization, laboratory testing, and packaging validation services to medical device and pharmaceutical manufacturers, supporting regulatory compliance in highly controlled settings. Its Life Sciences activities provide contamination-control equipment, sterilization and decontamination systems, and support services to biopharmaceutical, biotechnology, and research customers worldwide. Founded in 1985 and headquartered in Dublin, Ireland, with major operational presence in Mentor, Ohio, STERIS plc plays a central role in the infrastructure of modern healthcare and regulated manufacturing by enabling reliable infection prevention and sterile processing.

CEO Mr. Daniel A. Carestio · 17,937 employees · United States · https://www.steris.com